Dynavax Technologies Patent-Cliff Exposure & CMS Drug Spending Portfolio

Dynavax Technologies (Emeryville, CA): 1 reconciled FDA prescription therapies, $877K 2024 CMS Part D & Medicaid spend, and 4 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterEmeryville, CA
Reconciled FDA Portfolio Therapies1
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE DateMulti-asset schedule
2024 CMS Total Public Spend$877K
2024 Medicare Part D Spend$877K
2024 Medicaid Spend$0
California HCAI SB 17 Filings4 WAC filings (max 17.4% 2-yr change)